Phase I trial of elactocin

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 648-649

  Newlands, E S ^a   Rustin, G J S ^a   Brampton, M H ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Anti tumour antibiotics; Elactocin; Phase I trials

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; LEPTOMYCIN B;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; NAUSEA; PERITONITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0029737848     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.415     Document Type: Article

References (5)

1. LEOPOLD WR, SHILLIS JL, MERTUS AE, NELSON JM, ROBERTS BJ AND JACKSON RC. (1984). Anticancer activity of the structurally novel antibiotic Ci-920 and its analogues. Cancer Res., 44, 1928-1932.
2. ROBERTS BJ, HAMELEHLE KL, SELBOLT JS AND LEOPOLD WR. (1986). In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother. Pharmacol., 16, 95-101.
3. SCHAUMBERG JP, HOKANSON GC AND FRENCH JC. (1984). The structures of the anti-tumour antibiotics PD 114,720 and PD 114,721. J. Chem. Soc. Chem. Commun., 21, 1450-1452.
4. SLACK JA, QUARTERMAN CP, BAER JB AND FOX BW. (1990). Preclinical development of elactocin. Proc. Am. Assoc. Cancer Res., 31, 414 (NSC 364372). (Abstract no. 2459).
5. TUNAC JB, GRAHAM BD, DOBSON WE AND LENZINI MD. (1985). Novel antitumour antibiotics, Cl-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity. J. Antibiotics, 38, 460-465.